Plain-English translation of NCT06550063 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is looking at a protein called HER2 that appears on some stomach and esophagus cancer cells. Researchers want to understand how common this protein is, how it varies between patients, and whether it can help predict which treatments will work best for you.
Doctors now know that targeted treatments work better for some patients whose cancers have this HER2 protein. However, we don't have enough information about how often it appears in different parts of the world, how it changes within a single tumor, or what it means for patients being treated with the goal of curing their cancer rather than just managing it.
You likely qualify if…
You likely don't qualify if…
This is not a treatment study — you won't receive any new medication or undergo new procedures. Instead, researchers will review your medical records, pathology reports, and test results from your cancer diagnosis and treatment. Your information will be combined with data from nearly 2,200 other patients worldwide to identify patterns about the HER2 protein and how it relates to treatment outcomes.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Ireland
Enrollment target
~2,188 participants
Started
August 2024
Primary completion
May 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Last updated on clinicaltrials.gov in August 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Nicola B Raftery, MBBCh,MSc
Trinity St James Cancer Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.